Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2010

View Archived Issues

Interim results from phase I study on anti-ALK-1 mAb PF-03446962 in solid tumors presented

Preliminary phase I data on HDAC inhibitor CHR-3996 in advanced solid tumors disclosed

Banyu discovers Wee1 kinase inhibitors for cancer therapy

Janssen claims new fatty acid amide hydrolase inhibitors

AstraZeneca presents new antimycobacterial agents

Euroscreen claims new GPR43 agonists/partial agonists

Novel DDAH inhibitors disclosed by German scientists

GPR119 agonist AS-1535907 regulates insulin expression and pancreatic beta-cell mass in vivo

CRASH-2 findings support use of tranexamic acid in trauma patients with significant bleeding

Genetic profiles of patients responding to antihypertensive rostafuroxine identified

InNexus develops protein for potential use in AMD

Sangamo receives funding to develop Parkinson's disease treatment

Phosphagenics to assess dosing regimen for its transdermal oxycodone patch

GSK and Genmab amend ofatumumab agreement

Evotec starts phase II study of EVT-101 in treatment-resistant depression

FDA grants Cyclacel orphan designation for sapacitabine in AML and MDS

Final data from Zadaxin study show enhanced immune response after vaccination

Oxygen reports porcine animal model results for Oxycyte in decompression sickness

Sanofi-aventis and JDRF partner for type 1 diabetes therapeutics

MorphoSys achieves milestone in antibody partnership with Novartis

Phase III study of Avastin combined with chemotherapy meets primary endpoint

Javelin to become fully owned subsidiary of Hospira

Intercell reports results from phase II trial of Vaccine Enhancement Patch

Lilly set to acquire Alnara and its PERT therapy liprotamase

Otsuka and MethylGene extend collaboration for kinase inhibitors in ocular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...